Marinus Pharma rises on U.S. launch of seizure treatment

Marinus Pharmaceuticals

28/07/2022 14:18

** Shares of Marinus Pharmaceuticals Inc  MRNS.O  rise 2.3%
to $5.99 premarket
    ** Co reports U.S. commercial launch of its seizure
treatment, Ztalmy  urn:newsml:reuters.com:*:nBw3ndfTja
    ** Ztalmy is intended to treat seizures associated with
CDKL5 deficiency disorder, a rare genetic epilepsy 
    ** It was approved by U.S. FDA in March
    ** As of last close, shares had fallen ~50.8% YTD 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))